SHPL-49 / Hutchmed - LARVOL DELTA

SAIL: Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke (clinicaltrials.gov) - P3 | N=1096 | Recruiting | Sponsor: Shanghai Hutchison Pharmaceuticals Limited | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Ischemic stroke

Salidroside derivative SHPL-49 accelerates cutaneous wound healing in diabetic mice by modulating macrophage-mediated TGF-β1/Smad2/3 signaling pathway. (PubMed, Toxicol Appl Pharmacol) - "Collectively, our findings suggest that SHPL-49 is a promising therapeutic candidate for diabetic wound healing, functioning through a macrophage-to-fibroblast signaling axis: it polarizes macrophages toward an M2 phenotype, which subsequently release TGF-β1 to enhance fibroblast function via the Smad2/3 signaling pathway. This study establishes a theoretical foundation for the future exploration and development of novel therapeutic indications for SHPL-49."

Journal • Preclinical • Diabetes • Metabolic Disorders • MRC1 • TGFB1

SAIL: Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke (clinicaltrials.gov) - P3 | N=1096 | Not yet recruiting | Sponsor: Shanghai Hutchison Pharmaceuticals Limited

New P3 trial • Cardiovascular • Ischemic stroke